From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

Sai-Hong Ignatius Ou is the Hamoui Salous Endowed chair in Thoracic Oncology Research and Health Science Clinical Professor at University of California Irvine School of Medicine. Professor Ou is the editor-in-chief for Lung Cancer: Targets and Therapy (Dove Press), associate editor for Journal of Thoracic Oncology, and serves on the editorial board of Annals of Oncology and Clinical Lung Cancer. Professor Ou has been involved in targeted therapy in NSCLC for 20 years.

留言 (0)

沒有登入
gif